Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

36.38 +11.18 (+44.37%)
Delayed Quote Updated: 3:17 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Top stock movements in today's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Why Pacira BioSciences Skyrocketed Today ↗
The specialty pharmaceutical company is being acquired. 
Via The Motley Fool
Traders are paying attention to the gapping stocks in Thursday's session. ↗
Via Chartmill
Pacira Biosciences (NASDAQ:PCRX): An Undervalued Value Stock Backed by Cash Flow and Balance Sheet Strength ↗
Via Chartmill
Pacira Biosciences (NASDAQ:PCRX): A Value Play with Fundamentals Intact ↗
Via Chartmill
Pacira Biosciences (NASDAQ:PCRX) Beats Q2 EPS Estimates, Misses on Revenue and Cuts Outlook ↗
Via Chartmill
Pacira Biosciences Inc (NASDAQ:PCRX) Emerges as a Deep Value Opportunity with Strong Financial Health ↗
Via Chartmill
News headline image
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira (PCRX) Q2 2026 Earnings Call Transcript ↗
EXPAREL revenue grew 3% while company divested iovera and expanded insurance coverage. 
Via The Motley Fool
Topics Earnings
News headline image
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Q2 Earnings Call Highlights ↗
Pacira BioSciences (NASDAQ:PCRX) reported second-quarter 2026 revenue growth, led by higher sales of its EXPAREL, ZILRETTA and iovera° products, while highlighting expanded payer coverage, pipeline... 
Via MarketBeat
Topics Earnings
News headline image
Pacira BioSciences Reports Second Quarter 2026 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
From Pacira BioSciences
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
From Pacira BioSciences
Via GlobeNewswire
News headline image
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
Issued on behalf of Conexeu Sciences Inc. 
From Biotech Insider
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy
From Pacira BioSciences
Via GlobeNewswire
News headline image
A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching
Issued on behalf of Conexeu Sciences Inc. 
From World Street Intelligence
Via GlobeNewswire
News headline image
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
From Pacira BioSciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.